Sign In
Buy REGN
$618.95
+16.03 (+2.66%)
At Close: Jun 03, 2026
Intellia Therapeutics Is Pushing CRISPR-Based Therapy Forward, Slowly But Surely
05:31am, Saturday, 30'th Jul 2022 Seeking Alpha
Intellia’s recent data from its Regeneron collaboration for CRISPR-based NTLA-2001 shows a durable response to the lead in vivo genome editing candidate.
Alnylam's (ALNY) Earnings and Revenues Lag Estimates in Q2
03:01pm, Friday, 29'th Jul 2022 Zacks Investment Research
Alnylam's (ALNY) earnings and sales fall shy of estimates in the second quarter of 2022. The company maintains its revenue guidance for 2022.
What is in Store for Regeneron (REGN) This Earnings Season?
02:20pm, Friday, 29'th Jul 2022 Zacks Investment Research
Regeneron's (REGN) second-quarter earnings might have gotten a boost from the solid performance of Eylea and Dupixent.
Sanofi (SNY) Q2 Earnings & Sales Beat, Ups 2022 Growth View
04:11pm, Thursday, 28'th Jul 2022 Zacks Investment Research
Sanofi (SNY) beats second-quarter estimates for earnings and sales. Dupixent drives sales growth and a strong recovery in travel vaccines. The company raises its earnings growth guidance for 2022.
Will Insmed (INSM) Report Negative Earnings Next Week? What You Should Know
02:03pm, Thursday, 28'th Jul 2022 Zacks Investment Research
Insmed (INSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Regeneron (REGN) to Report a Decline in Earnings: What to Look Out for
02:01pm, Wednesday, 27'th Jul 2022 Zacks Investment Research
Regeneron (REGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Regeneron (REGN) Outpaces Stock Market Gains: What You Should Know
10:00pm, Monday, 25'th Jul 2022 Zacks Investment Research
Regeneron (REGN) closed the most recent trading day at $587.28, moving +0.2% from the previous trading session.
Regeneron's Price Target Cut On Dim Prospects For Its Flagship Eye Product
04:25pm, Monday, 25'th Jul 2022 Benzinga
SVB has cut the price target from $738 to $630 and downgraded from Outperform to Market Perform to reflect Regeneron Pharmaceutical Inc's (NASDAQ: REGN) acquisition of Libtayo ex-US rights from
Benzinga's Top Ratings Upgrades, Downgrades For July 25, 2022
02:22pm, Monday, 25'th Jul 2022 Benzinga
Upgrades
For AutoNation Inc (NYSE:AN), Seaport Global upgraded the previous rating of Neutral to Buy. In the second quarter, AutoNation showed an EPS of $6.48, compared to $4.83 from the year-ago quar
Meta Platforms To $250? Plus This Analyst Lowers Price Target On Microsoft
12:31pm, Monday, 25'th Jul 2022 Benzinga
Morgan Stanley boosted the price target for American Express Company (NYSE: AXP) from $143 to $155. American Express shares rose 0.1% to $153.15 in pre-market trading.
Oppenheimer cut the price targ
2 Pharma Giants With Momentum That Could Carry Through 2030
03:30pm, Friday, 22'nd Jul 2022 The Motley Fool
An obese population could drive competition toward a valuable market.
Roche (RHHBY) 1H22 Earnings, Sales Grow, View Disappoints
04:04pm, Thursday, 21'st Jul 2022 Zacks Investment Research
Roche (RHHBY) performance in the first half was decent on demand for its diagnostics base business and new drugs. Demand for COVID-19 tests is likely to fall in the second half.
Where Regeneron Pharmaceuticals Stands With Analysts
05:06pm, Wednesday, 20'th Jul 2022 Benzinga
Over the past 3 months, 10 analysts have published their opinion on Regeneron Pharmaceuticals (NASDAQ:REGN) stock. These analysts are typically employed by large Wall Street banks and tasked with unde
3 High-Margin Businesses That Can Absorb Inflation
03:45pm, Wednesday, 20'th Jul 2022 The Motley Fool
These companies regularly post gross margins of 80% or better.
3 High-Margin Businesses That Can Absorb Inflation
11:45am, Wednesday, 20'th Jul 2022
These companies regularly post gross margins of 80% or better.
